gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by COVAXX

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): UB-612

            Therapeutic Area: Infections and Infectious Diseases Product Name: UB-612

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Ministry of Health and Welfare, Taiwan

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Funding September 28, 2020

            Details:

            The Phase 1 open-label trial is designed to evaluate the safety, tolerability, and immunogenicity of UB-612, a multitope peptide-based vaccine candidate against COVID-19 based on a platform that allows for the cost-effective production of vaccines at scale.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): UB-612

            Therapeutic Area: Infections and Infectious Diseases Product Name: UB-612

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: University of Nebraska Medical Center

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 11, 2020

            Details:

            With respect to the COVID-19 pandemic, UNMC trials will focus preliminarily on conducting Phase I/II human trials in the United States of COVAXX's UB-612 vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Multitope Peptide-based Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            COVAXX has developed a well-balanced B-cell and T-cell vaccine designed to activate both arms of the patient’s humoral and cellular immune responses. The candidate vaccine is constructed off a commercially proven peptide-based vaccine platform deployed by United Biomedical.